✦ LIBER ✦

Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.

✍ Scribed by C.-P. Schneider; U. Merkel; U. Grübner; R. Kath; K. Höffken; A. Hoffmann

Publisher: Springer-Verlag
Year: 2002
Tongue: English
Weight: 89 KB
Volume: 128
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-002-0337-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of docetaxel and topotecan

Phase I study of docetaxel and topotecan in patients with solid tumors

✍ Katherine H. Tkaczuk; William C. Zamboni; Nancy S. Tait; Barry R. Meisenberg; L. 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 103 KB

Phase I and pharmacokinetic study of UCN

Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors

✍ Antonio Jimeno; Michelle A. Rudek; Thomas Purcell; Daniel A. Laheru; Wells A. Me 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 438 KB

Phase I study of the combination of topo

Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors

✍ Carlos Rodriguez-Galindo; Kristine R. Crews; Clinton F. Stewart; Wayne Furman; J 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 271 KB

Irinotecan in combination with thalidomi

Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation

✍ Giacomo Allegrini; Antonello Di Paolo; Elisa Cerri; Samanta Cupini; Federica Ama 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 249 KB

Phase I clinical and pharmacokinetic stu

Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agentd-19575 (glufosfamide) in patients with solid tumors

✍ Toshio Shimizu; Isamu Okamoto; Kenji Tamura; Taroh Satoh; Masaki Miyazaki; Yusak 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 456 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi